← 產業報告目錄

POP Treatment and Management / Pelvic Organ Prolapse Market by Product (Synthetic Mesh, Sutures, Pessaries, Robotic Systems), Treatment (Surgical, PFMT), Application (Cystocele, Uterine Prolapse), End User (Hospitals, ASCs), Region - Global Forecast to 2030

出版商 MarketsandMarkets產業別 Medical Devices出版日期 2025-10-17頁數 332報告編號 MD9567

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The global POP Treatment and Management / Pelvic Organ Prolapse market is projected to reach USD 1.06 billion by 2030 from USD 0.77 billion in 2025, at a CAGR of 6.6% during the forecast period. The market is expected to witness high growth due to the high global prevalence of pelvic organ prolapse, rising geriatric female population, growing awareness and early diagnosis, and advancements in minimally invasive and robotic surgical techniques. Complications and recalls associated with vaginal mesh, limited access and affordability in developing markets, underdiagnosis due to social stigma, and the risk of POP products are likely to restrain market growth. “The hospitals segment of the POP Treatment and Management / Pelvic Organ Prolapse market, by end user, is expected to hold the largest position during the forecast period.” Based on end user, the market is segmented into hospitals, specialty clinics, ambulatory surgery centers (ASCs), and others. In 2024, hospitals and clinics accounted for the largest share of the market. Hospitals benefit from centralized procurement systems, allowing for efficient integration of new POP technologies. Their access to government or institutional funding also facilitates the acquisition of expensive devices, such as robotic surgical systems, which may not be feasible in smaller outpatient facilities. Furthermore, hospitals are often the only facilities equipped to manage intraoperative complications, complex reconstructions, and comorbid conditions in elderly patients—ensuring their continued dominance in the pelvic organ prolapse treatment landscape. “The surgical segment accounted for the larger market share in the POP Treatment and Management / Pelvic Organ Prolapse market.” The POP Treatment and Management / Pelvic Organ Prolapse market is segmented into surgical and non-surgical. The surgical segment accounted for the larger share of the market in 2024. Surgical intervention is often preferred in cases involving multiple-compartment prolapses or associated conditions like stress urinary incontinence. Moreover, with the growing availability of minimally invasive and robotic-assisted methods, surgical options now offer quicker recovery and reduced postoperative complications, making them more acceptable to both patients and clinicians. Continuous innovation in surgical meshes, biologic grafts, and energy-assisted dissection tools further enhances procedural outcomes. Importantly, surgical treatments are backed by strong clinical guidelines and are often the first-line recommendation in moderate to severe POP, reinforcing their dominant position in the market. “Asia Pacific is the fastest-growing market for POP Treatment and Management / Pelvic Organ Prolapse.” The global POP Treatment and Management / Pelvic Organ Prolapse market is segmented into five segments, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Asia Pacific is experiencing rapid population aging, especially in countries like China and Japan, leading to a rising incidence of pelvic organ prolapse disorders among elderly women. Increasing awareness of women’s health and growing acceptance of pelvic floor treatments are driving higher diagnosis and treatment rates. Governments across the region are investing in healthcare infrastructure, expanding access to surgical facilities, and supporting the adoption of advanced medical technologies, including robotic-assisted procedures. The rise of medical tourism in countries such as India and South Korea further fuels market growth, offering high-quality care at lower costs. While access disparities and a shortage of trained specialists still exist in rural areas, ongoing investments in healthcare training, digital health platforms, and public awareness campaigns are helping to close these gaps, positioning Asia Pacific as the fastest-growing regional market. A breakdown of the primary participants referred to for this report is provided below: • By Company Type: Tier 1: 40%, Tier 2: 30%, and Tier 3: 30% • By Designation: C Level: 27%, Director Level: 18%, and Others: 55% • By Region: North America: 51%, Europe: 21%, Asia Pacific: 18%, Latin America: 6%, and Middle East & Africa: 4% Note 1: Companies are classified into tiers based on their total revenue. As of 2024, Tier 1 = >USD 10.00 billion, Tier 2 = USD 1.00 billion to USD 10.00 billion, and Tier 3 = <USD 1.00 billion. Note 2: C-level primaries include CEOs, CFOs, COOs, and VPs. Note 3: Other designations include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers. The major players operating in the POP Treatment and Management / Pelvic Organ Prolapse market are Boston Scientific Corporation (US), Coloplast Group (Denmark), Intuitive Surgical Operations, Inc. (US), CooperCompanies (US), and Johnson & Johnson (US). Research Coverage This report studies the POP Treatment and Management / Pelvic Organ Prolapse market based on product, treatment, application, end user, and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends. It forecasts the revenue of the market segments with respect to five major regions (and the respective countries in these regions). Reasons to Buy the Report The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, will help them to garner a larger market share. Firms purchasing the report could use one or a combination of the strategies mentioned below to strengthen their market presence. This report provides insights into the following pointers: Analysis of key drivers (High global prevalence of pelvic organ prolapse, rising geriatric female population, growing awareness and early diagnosis, and advancements in minimally invasive and robotic surgical techniques), restraints (complications and recalls associated with vaginal mesh, limited access and affordability in developing market, and underdiagnosis due to social stigma), opportunities (growth opportunities in emerging economies, development of bioengineered and absorbable mesh and digital health and pelvic floor therapy devices), and challenges (inconsistent clinical guidelines and treatment standards, and high recurrence and reoperation rates) Market Penetration: Comprehensive information on the product portfolios offered by the top players in the POP Treatment and Management / Pelvic Organ Prolapse market Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the POP Treatment and Management / Pelvic Organ Prolapse market Market Development: Comprehensive information on lucrative emerging regions Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the POP Treatment and Management / Pelvic Organ Prolapse market Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players
目錄 Table of Contents
1 INTRODUCTION 30 1.1 STUDY OBJECTIVES 30 1.2 MARKET DEFINITION 30 1.3 STUDY SCOPE 31 1.3.1 MARKETS COVERED AND REGIONAL SCOPE 31 1.3.2 INCLUSIONS AND EXCLUSIONS 32 1.3.3 YEARS CONSIDERED 33 1.4 CURRENCY CONSIDERED 33 1.5 STAKEHOLDERS 33 2 RESEARCH METHODOLOGY 34 2.1 RESEARCH DATA 34 2.1.1 SECONDARY DATA 35 2.1.1.1 List of secondary sources 35 2.1.1.2 Key data from secondary sources 35 2.1.2 PRIMARY DATA 36 2.1.2.1 List of primary sources 36 2.1.2.2 Key data from primary sources 37 2.1.2.3 Breakdown of primary interviews 38 2.1.2.4 Insights from industry experts 38 2.2 MARKET SIZE ESTIMATION 39 2.2.1 BOTTOM-UP APPROACH 39 2.2.1.1 Approach 1: Revenue estimation of key players 39 2.2.1.2 Approach 2: Study of annual reports and investor presentations 39 2.2.1.3 Approach 3: Primary interviews 40 2.2.1.4 Growth forecast 40 2.2.1.5 CAGR projections 40 2.2.2 TOP-DOWN APPROACH 41 2.3 DATA TRIANGULATION 42 2.4 RESEARCH ASSUMPTIONS 43 2.4.1 STUDY-RELATED ASSUMPTIONS 43 2.4.2 PARAMETRIC ASSUMPTIONS 43 2.4.3 GROWTH RATE ASSUMPTIONS 43 2.5 RESEARCH LIMITATIONS 44 2.6 RISK ASSESSMENT 44 3 EXECUTIVE SUMMARY 45   4 PREMIUM INSIGHTS 51 4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN PELVIC ORGAN PROLAPSE/ PELVIC FLOOR RECONSTRUCTION MARKET 51 4.2 ASIA PACIFIC PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY END USER AND COUNTRY 52 4.3 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY REGION 53 4.4 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY COUNTRY 54 5 MARKET OVERVIEW 55 5.1 INTRODUCTION 55 5.2 MARKET DYNAMICS 55 5.2.1 DRIVERS 56 5.2.1.1 Global prevalence of pelvic organ prolapse 56 5.2.1.2 Rise in female geriatric population 56 5.2.1.3 Improved awareness and early diagnosis 57 5.2.1.4 Advancements in robotic surgical techniques 57 5.2.2 RESTRAINTS 58 5.2.2.1 Complications and recalls associated with transvaginal synthetic mesh 58 5.2.2.2 Limited access in emerging economies 58 5.2.2.3 Underdiagnosis due to social stigma 58 5.2.3 OPPORTUNITIES 59 5.2.3.1 Increased investments in pelvic organ prolapse care from emerging economies 59 5.2.3.2 Rapid development of bioengineered and absorbable mesh 59 5.2.3.3 Advent of digital pelvic health solutions 60 5.2.4 CHALLENGES 60 5.2.4.1 Inconsistent clinical guidelines and treatment standards 60 5.2.4.2 High recurrence and reoperation rates 60 5.3 TRENDS AND DISRUPTIONS IMPACTING CUSTOMER BUSINESS 61 5.4 PRICING ANALYSIS 61 5.4.1 AVERAGE SELLING PRICE TREND, BY PRODUCT 61 5.4.2 AVERAGE SELLING PRICE TREND, BY TREATMENT AND KEY PLAYER 62 5.4.3 AVERAGE SELLING PRICE TREND, BY REGION 63 5.5 VALUE CHAIN ANALYSIS 63 5.6 SUPPLY CHAIN ANALYSIS 65 5.7 ECOSYSTEM ANALYSIS 66 5.8 INVESTMENT AND FUNDING SCENARIO 67 5.9 TECHNOLOGY ANALYSIS 68 5.9.1 KEY TECHNOLOGIES 68 5.9.1.1 Pelvic mesh implants 68 5.9.1.2 Vaginal pessaries 69   5.9.2 COMPLEMENTARY TECHNOLOGIES 69 5.9.2.1 Wearable and app-based pelvic therapy devices 69 5.9.3 ADJACENT TECHNOLOGIES 69 5.9.3.1 Urinary incontinence devices 69 5.10 PATENT ANALYSIS 70 5.11 TRADE ANALYSIS 72 5.11.1 IMPORT SCENARIO (HS CODE 901890) 72 5.11.2 EXPORT SCENARIO (HS CODE 901890) 73 5.12 KEY CONFERENCES AND EVENTS, 2025–2026 73 5.13 CASE STUDY ANALYSIS 74 5.13.1 NEGLECTED PESSARY IN PATIENT WITH PELVIC ORGAN PROLAPSE 74 5.13.2 SUCCESSFUL USE OF PESSARY FOR UTERINE PROLAPSE AFTER PELVIC TRAUMA IN YOUNG, NULLIPAROUS FEMALE 74 5.13.3 ROBOTIC AND LAPAROSCOPIC SACROCOLPOPEXY FOR PELVIC ORGAN PROLAPSE 75 5.14 REGULATORY LANDSCAPE 75 5.14.1 REGULATORY ANALYSIS 75 5.14.1.1 North America 75 5.14.1.1.1 US 75 5.14.1.1.2 Canada 75 5.14.1.2 Europe 76 5.14.1.2.1 Germany 76 5.14.1.2.2 UK 76 5.14.1.2.3 France 76 5.14.1.3 Asia Pacific 77 5.14.1.3.1 China 77 5.14.1.3.2 Japan 77 5.14.1.3.3 India 77 5.14.1.4 Latin America 78 5.14.1.5 Middle East 78 5.14.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 78 5.15 PORTER’S FIVE FORCES ANALYSIS 80 5.15.1 BARGAINING POWER OF SUPPLIERS 81 5.15.2 BARGAINING POWER OF BUYERS 81 5.15.3 THREAT FROM NEW ENTRANTS 81 5.15.4 THREAT FROM SUBSTITUTES 81 5.15.5 INTENSITY OF COMPETITIVE RIVALRY 82 5.16 KEY STAKEHOLDERS AND BUYING CRITERIA 82 5.16.1 KEY STAKEHOLDERS IN BUYING PROCESS 82 5.16.2 BUYING CRITERIA 83   5.17 IMPACT OF AI 84 5.17.1 INTRODUCTION 84 5.17.2 POTENTIAL OF AI IN PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET 84 5.17.3 KEY COMPANIES IMPLEMENTING AI 85 5.17.4 FUTURE OF AI IN PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET 86 5.18 US 2025 TARIFF 86 5.18.1 INTRODUCTION 86 5.18.2 KEY TARIFF RATES 87 5.18.3 PRICE IMPACT ANALYSIS 88 5.18.4 IMPACT ON COUNTRY/REGION 88 5.18.4.1 North America 88 5.18.4.2 Europe 88 5.18.4.3 Asia Pacific 88 5.18.5 IMPACT ON END-USE INDUSTRIES 89 5.18.5.1 Hospitals 89 6 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY PRODUCT 90 6.1 INTRODUCTION 91 6.2 SYNTHETIC MESH 91 6.2.1 ADOPTION OF ADVANCED, PATIENT-FOCUSED MESH TECHNOLOGIES 91 6.3 BIOLOGICAL GRAFTS 95 6.3.1 SHIFT TOWARD BIOCOMPATIBLE ALTERNATIVES 95 6.4 SUTURES 98 6.4.1 NEED FOR PRECISION IN PELVIC REPAIRS WITH ABSORBABLE AND ANTIBACTERIAL PRODUCTS 98 6.5 VAGINAL PESSARIES 102 6.5.1 INTRODUCTION OF CUSTOM-FIT, HOME-USE PESSARY SOLUTIONS 102 6.6 PELVIC FLOOR THERAPY DEVICES 106 6.6.1 PATIENT PREFERENCE FOR MANAGING PELVIC FLOOR DISORDERS INDEPENDENTLY 106 6.7 ROBOTIC SURGERY SYSTEMS 109 6.7.1 ELEVATED DEMAND FOR MINIMALLY INVASIVE SOLUTIONS IN COMPLEX PELVIC REPAIRS 109 6.8 DIAGNOSTIC & ASSESSMENT TOOLS 112 6.8.1 ACCURATE DETECTION WITH ADVANCED IMAGING AND SMART DEVICES 112   7 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TREATMENT 116 7.1 INTRODUCTION 117 7.2 SURGICAL 117 7.2.1 COLPOCLEISIS 121 7.2.1.1 Large-scale adoption among older women 121 7.2.2 COLPORRHAPY 124 7.2.2.1 Increased preference for foundational repair techniques 124 7.2.3 SACROCOLPOPEXY 127 7.2.3.1 Reduced postoperative discomfort and quicker recovery 127 7.2.4 SACROHYSTEROPEXY 130 7.2.4.1 Rise in demand for uterine-preserving options for prolapse repair 130 7.2.5 UTEROSACRAL OR SACROSPINOUS LIGAMENT FIXATION 133 7.2.5.1 Surge in native tissue repairs without mesh-based interventions 133 7.3 NON-SURGICAL 136 7.3.1 VAGINAL PESSARY MANAGEMENT 139 7.3.1.1 Emphasis on early intervention 139 7.3.2 PELVIC FLOOR MUSCLE THERAPY 142 7.3.2.1 Extensive use in early-stage prolapse and postpartum women 142 8 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY APPLICATION 145 8.1 INTRODUCTION 146 8.2 CYSTOCELE 146 8.2.1 WEAKENED PELVIC FLOOR MUSCLES PROMPT DEVELOPMENT 146 8.3 URETHROCELE 149 8.3.1 CHRONIC INCREASE IN INTRA-ABDOMINAL PRESSURE 149 8.4 ENTEROCELE 152 8.4.1 SURGE IN APICAL VAGINAL SUPPORT DEFICIENCY 152 8.5 UTERINE PROLAPSE 155 8.5.1 GROWTH IN PROLAPSE BURDEN 155 8.6 RECTOCELE 158 8.6.1 PREVALENCE OF RECTOVAGINAL SEPTUM DEFICIENCY 158 9 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY END USER 162 9.1 INTRODUCTION 163 9.2 HOSPITALS 163 9.2.1 HIGH PATIENT INFLOW AND WIDESPREAD AVAILABILITY OF REIMBURSEMENTS 163   9.3 SPECIALTY CLINICS 167 9.3.1 HEIGHTENED DEMAND FOR TAILORED, NON-INVASIVE, AND ACCESSIBLE CARE 167 9.4 AMBULATORY SURGERY CENTERS 170 9.4.1 COST ADVANTAGES AND FAVORABLE CLINICAL OUTCOMES 170 9.5 OTHER END USERS 173 10 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY REGION 177 10.1 INTRODUCTION 178 10.2 NORTH AMERICA 178 10.2.1 MACROECONOMIC OUTLOOK 179 10.2.2 US 184 10.2.2.1 Rise in female geriatric population to drive market 184 10.2.3 CANADA 188 10.2.3.1 High symptom prevalence and demographic trends to drive market 188 10.3 EUROPE 191 10.3.1 MACROECONOMIC OUTLOOK 191 10.3.2 GERMANY 196 10.3.2.1 Advanced surgical innovations to drive market 196 10.3.3 FRANCE 199 10.3.3.1 Increased clinical focus on pelvic floor disorders and pelvic organ prolapse to drive market 199 10.3.4 UK 203 10.3.4.1 Women's health policy initiatives to drive market 203 10.3.5 ITALY 207 10.3.5.1 Demographic shifts to drive market 207 10.3.6 SPAIN 211 10.3.6.1 Rising popularity of non-surgical interventions to drive market 211 10.3.7 REST OF EUROPE 214 10.4 ASIA PACIFIC 218 10.4.1 MACROECONOMIC OUTLOOK 218 10.4.2 CHINA 223 10.4.2.1 Growing incidence of pelvic organ prolapse to drive market 223 10.4.3 JAPAN 227 10.4.3.1 Evolving healthcare delivery and infrastructure landscape to drive market 227 10.4.4 INDIA 231 10.4.4.1 Booming medical tourism to drive market 231 10.4.5 AUSTRALIA 235 10.4.5.1 Rapid growth of medical manufacturing companies to drive market 235 10.4.6 SOUTH KOREA 239 10.4.6.1 Surge in healthcare spending to drive market 239 10.4.7 REST OF ASIA PACIFIC 242 10.5 LATIN AMERICA 246 10.5.1 MACROECONOMIC OUTLOOK 246 10.5.2 BRAZIL 250 10.5.2.1 Improving healthcare infrastructure to drive market 250 10.5.3 MEXICO 254 10.5.3.1 Expanding healthcare awareness and services to drive market 254 10.5.4 REST OF LATIN AMERICA 257 10.6 MIDDLE EAST & AFRICA 261 10.6.1 MACROECONOMIC OUTLOOK 261 11 COMPETITIVE LANDSCAPE 265 11.1 INTRODUCTION 265 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2022–2025 265 11.3 REVENUE ANALYSIS, 2022–2024 267 11.4 MARKET SHARE ANALYSIS, 2024 267 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 270 11.5.1 STARS 270 11.5.2 EMERGING LEADERS 270 11.5.3 PERVASIVE PLAYERS 270 11.5.4 PARTICIPANTS 270 11.5.5 COMPANY FOOTPRINT 272 11.5.5.1 Company footprint 272 11.5.5.2 Region footprint 272 11.5.5.3 Product footprint 273 11.5.5.4 Treatment footprint 274 11.5.5.5 Application footprint 274 11.6 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2024 275 11.6.1 PROGRESSIVE COMPANIES 275 11.6.2 RESPONSIVE COMPANIES 275 11.6.3 DYNAMIC COMPANIES 275 11.6.4 STARTING BLOCKS 275 11.6.5 COMPETITIVE BENCHMARKING 277 11.6.5.1 List of start-ups/SMEs 277 11.6.5.2 Competitive benchmarking of start-ups/SMEs 278 11.7 COMPANY VALUATION AND FINANCIAL METRICS 279 11.8 BRAND/PRODUCT COMPARISON 280 11.9 COMPETITIVE SCENARIO 281 11.9.1 PRODUCT LAUNCHES/APPROVALS 281 11.9.2 DEALS 282 11.9.3 OTHER DEVELOPMENTS 283 12 COMPANY PROFILES 284 12.1 KEY PLAYERS 284 12.1.1 BOSTON SCIENTIFIC CORPORATION 284 12.1.1.1 Business overview 284 12.1.1.2 Products offered 285 12.1.1.3 Recent developments 286 12.1.1.3.1 Deals 286 12.1.1.4 MnM view 286 12.1.1.4.1 Right to win 286 12.1.1.4.2 Strategic choices 286 12.1.1.4.3 Weaknesses and competitive threats 286 12.1.2 COLOPLAST GROUP 287 12.1.2.1 Business overview 287 12.1.2.2 Products offered 289 12.1.2.3 MnM view 289 12.1.2.3.1 Right to win 289 12.1.2.3.2 Strategic choices 289 12.1.2.3.3 Weaknesses and competitive threats 289 12.1.3 INTUITIVE SURGICAL OPERATIONS, INC. 290 12.1.3.1 Business overview 290 12.1.3.2 Products offered 291 12.1.3.3 Recent developments 292 12.1.3.3.1 Product launches/approvals 292 12.1.3.4 MnM view 292 12.1.3.4.1 Right to win 292 12.1.3.4.2 Strategic choices 292 12.1.3.4.3 Weaknesses and competitive threats 292 12.1.4 COOPERCOMPANIES 293 12.1.4.1 Business overview 293 12.1.4.2 Products offered 294 12.1.4.3 Recent developments 295 12.1.4.3.1 Deals 295 12.1.4.4 MnM view 295 12.1.4.4.1 Right to win 295 12.1.4.4.2 Strategic choices 295 12.1.4.4.3 Weaknesses and competitive threats 295 12.1.5 JOHNSON & JOHNSON 296 12.1.5.1 Business overview 296 12.1.5.2 Products offered 297 12.1.5.3 Recent developments 298 12.1.5.3.1 Product launches/approvals 298 12.1.5.3.2 Deals 298 12.1.5.3.3 Other developments 298 12.1.5.4 MnM view 299 12.1.5.4.1 Right to win 299 12.1.5.4.2 Strategic choices 299 12.1.5.4.3 Weaknesses and competitive threats 299 12.1.6 GE HEALTHCARE 300 12.1.6.1 Business overview 300 12.1.6.2 Products offered 301 12.1.6.3 Recent developments 302 12.1.6.3.1 Product launches/approvals 302 12.1.6.3.2 Deals 302 12.1.6.3.3 Other developments 302 12.1.7 INTEGRA LIFESCIENCES CORPORATION 303 12.1.7.1 Business overview 303 12.1.7.2 Products offered 304 12.1.8 B. BRAUN SE 305 12.1.8.1 Business overview 305 12.1.8.2 Products offered 306 12.1.8.3 Recent developments 307 12.1.8.3.1 Deals 307 12.1.9 PFM MEDICAL GMBH 308 12.1.9.1 Business overview 308 12.1.9.2 Products offered 308 12.1.10 CALDERA MEDICAL 309 12.1.10.1 Business overview 309 12.1.10.2 Products offered 309 12.1.10.3 Recent developments 310 12.1.10.3.1 Deals 310 12.2 OTHER PLAYERS 311 12.2.1 KEGEL8 311 12.2.2 MEDGYN PRODUCTS INC. 312 12.2.3 BETATECH MEDICAL 313 12.2.4 FEG TEXTILTECHNIK FORSCHUNGS- UND ENTWICKLUNGSGESELLSCHAFT MBH 314 12.2.5 BIOTEQUE AMERICA INC. 315 12.2.6 PERSONAL MEDICAL CORP. 316 12.2.7 DIPROMED SRL 316 12.2.8 A.M.I. GMBH 317 12.2.9 BRAY GROUP 318 12.2.10 DIGITIMER LTD 319 12.2.11 MEDESIGN I.C. GMBH 320 12.2.12 DR. ARABIN GMBH & CO. KG 321 12.2.13 FOR.ME.SA. 322 12.2.14 COSM MEDICAL 322 12.2.15 WILLOW INNOVATIONS, INC. 323 13 APPENDIX 324 13.1 DISCUSSION GUIDE 324 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 328 13.3 CUSTOMIZATION OPTIONS 330 13.4 RELATED REPORTS 330 13.5 AUTHOR DETAILS 331
圖表清單 List of Tables & Figures
TABLE 1 POPULATION OF FEMALES AGED 50 AND ABOVE, 2024 56 TABLE 2 AVERAGE SELLING PRICING TREND OF PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION PRODUCTS, BY TYPE, 2023–2025 62 TABLE 3 AVERAGE SELLING PRICE TREND OF PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION PRODUCTS, BY TREATMENT AND KEY PLAYER, 2023–2025 62 TABLE 4 AVERAGE SELLING PRICE TREND OF PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION PRODUCTS, BY REGION, 2023–2025 63 TABLE 5 ROLE OF COMPANIES IN ECOSYSTEM 67 TABLE 6 PATENT ANALYSIS 71 TABLE 7 IMPORT DATA FOR HS CODE 901890-COMPLIANT PRODUCTS, BY COUNTRY, 2020–2024 (USD MILLION) 72 TABLE 8 EXPORT DATA FOR HS CODE 901890-COMPLIANT PRODUCTS, BY COUNTRY, 2020–2024 (USD MILLION) 73 TABLE 9 KEY CONFERENCES AND EVENTS, 2025–2026 73 TABLE 10 TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS IN JAPAN 77 TABLE 11 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 78 TABLE 12 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 79 TABLE 13 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 79 TABLE 14 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 79 TABLE 15 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 80 TABLE 16 IMPACT OF PORTER’S FIVE FORCES ON PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET 81 TABLE 17 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP FOUR PRODUCTS (%) 83 TABLE 18 KEY BUYING CRITERIA FOR TOP FOUR PRODUCTS 83 TABLE 19 US-ADJUSTED RECIPROCAL TARIFF RATES 87 TABLE 20 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 91 TABLE 21 KEY PRODUCTS IN SYNTHETIC MESH MARKET 92 TABLE 22 SYNTHETIC MESH SALES, BY COUNTRY, 2023–2030 (UNITS) 92 TABLE 23 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR SYNTHETIC MESH, BY REGION, 2023–2030 (USD MILLION) 93 TABLE 24 NORTH AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR SYNTHETIC MESH, BY COUNTRY, 2023–2030 (USD MILLION) 93 TABLE 25 EUROPE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR SYNTHETIC MESH, BY COUNTRY, 2023–2030 (USD MILLION) 94 TABLE 26 ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR SYNTHETIC MESH, BY COUNTRY, 2023–2030 (USD MILLION) 94 TABLE 27 LATIN AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR SYNTHETIC MESH, BY COUNTRY, 2023–2030 (USD MILLION) 95 TABLE 28 KEY PRODUCTS IN BIOLOGICAL GRAFTS MARKET 96 TABLE 29 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR BIOLOGICAL GRAFTS, BY REGION, 2023–2030 (USD MILLION) 96 TABLE 30 NORTH AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR BIOLOGICAL GRAFTS, BY COUNTRY, 2023–2030 (USD MILLION) 96 TABLE 31 EUROPE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR BIOLOGICAL GRAFTS, BY COUNTRY, 2023–2030 (USD MILLION) 97 TABLE 32 ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION FOR BIOLOGICAL GRAFTS, BY COUNTRY, 2023–2030 (USD MILLION) 97 TABLE 33 LATIN AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR BIOLOGICAL GRAFTS, BY COUNTRY, 2023–2030 (USD MILLION) 98 TABLE 34 KEY PRODUCTS IN SUTURES MARKET 98 TABLE 35 SUTURE SALES, BY COUNTRY, 2023–2030 (UNITS) 99 TABLE 36 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR SUTURES, BY REGION, 2023–2030 (USD MILLION) 99 TABLE 37 NORTH AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR SUTURES, BY COUNTRY, 2023–2030 (USD MILLION) 100 TABLE 38 EUROPE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR SUTURES, BY COUNTRY, 2023–2030 (USD MILLION) 100 TABLE 39 ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR SUTURES, BY COUNTRY, 2023–2030 (USD MILLION) 101 TABLE 40 LATIN AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR SUTURES, BY COUNTRY, 2023–2030 (USD MILLION) 101 TABLE 41 KEY PRODUCTS IN VAGINAL PESSARIES MARKET 102 TABLE 42 VAGINAL PESSARY SALES, BY COUNTRY, 2023–2030 (UNITS) 103 TABLE 43 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR VAGINAL PESSARIES, BY REGION, 2023–2030 (USD MILLION) 103 TABLE 44 NORTH AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR VAGINAL PESSARIES, BY COUNTRY, 2023–2030 (USD MILLION) 104 TABLE 45 EUROPE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR VAGINAL PESSARIES, BY COUNTRY, 2023–2030 (USD MILLION) 104 TABLE 46 ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR VAGINAL PESSARIES, BY COUNTRY, 2023–2030 (USD MILLION) 105 TABLE 47 LATIN AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR VAGINAL PESSARIES, BY COUNTRY, 2022–2030 (USD MILLION) 105 TABLE 48 KEY PRODUCTS IN PELVIC FLOOR THERAPY DEVICES MARKET 106 TABLE 49 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR PELVIC FLOOR THERAPY DEVICES, BY REGION, 2023–2030 (USD MILLION) 107 TABLE 50 NORTH AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR PELVIC FLOOR THERAPY DEVICES, BY COUNTRY, 2023–2030 (USD MILLION) 107 TABLE 51 EUROPE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR PELVIC FLOOR THERAPY DEVICES, BY COUNTRY, 2023–2030 (USD MILLION) 108 TABLE 52 ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR PELVIC FLOOR THERAPY DEVICES, BY COUNTRY, 2023–2030 (USD MILLION) 108 TABLE 53 LATIN AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR PELVIC FLOOR THERAPY DEVICES, BY COUNTRY, 2023–2030 (USD MILLION) 109 TABLE 54 KEY PRODUCTS IN ROBOTIC SURGERY SYSTEMS MARKET 109 TABLE 55 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR ROBOTIC SURGERY SYSTEMS, BY REGION, 2023–2030 (USD MILLION) 110 TABLE 56 NORTH AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR ROBOTIC SURGERY SYSTEMS, BY COUNTRY, 2023–2030 (USD MILLION) 110 TABLE 57 EUROPE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR ROBOTIC SURGERY SYSTEMS, BY COUNTRY, 2023–2030 (USD MILLION) 111 TABLE 58 ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR ROBOTIC SURGERY SYSTEMS, BY COUNTRY, 2023–2030 (USD MILLION) 111 TABLE 59 LATIN AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR ROBOTIC SURGERY SYSTEMS, BY COUNTRY, 2023–2030 (USD MILLION) 112 TABLE 60 KEY PRODUCTS IN DIAGNOSTIC & ASSESSMENT TOOLS MARKET 113 TABLE 61 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR DIAGNOSTIC & ASSESSMENT TOOLS, BY REGION, 2023–2030 (USD MILLION) 113 TABLE 62 NORTH AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR DIAGNOSTIC & ASSESSMENT TOOLS, BY COUNTRY, 2023–2030 (USD MILLION) 113 TABLE 63 EUROPE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR DIAGNOSTIC & ASSESSMENT TOOLS, BY COUNTRY, 2023–2030 (USD MILLION) 114 TABLE 64 ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR DIAGNOSTIC & ASSESSMENT TOOLS, BY COUNTRY, 2023–2030 (USD MILLION) 114 TABLE 65 LATIN AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR DIAGNOSTIC & ASSESSMENT TOOLS, BY COUNTRY, 2023–2030 (USD MILLION) 115 TABLE 66 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TREATMENT, 2023–2030 (USD MILLION) 117 TABLE 67 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR SURGICAL, BY TYPE, 2023–2030 (USD MILLION) 118 TABLE 68 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR SURGICAL, BY REGION, 2023–2030 (USD MILLION) 118 TABLE 69 NORTH AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR SURGICAL, BY COUNTRY, 2023–2030 (USD MILLION) 119 TABLE 70 EUROPE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR SURGICAL, BY COUNTRY, 2023–2030 (USD MILLION) 119 TABLE 71 ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR SURGICAL, BY COUNTRY, 2023–2030 (USD MILLION) 120 TABLE 72 LATIN AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR SURGICAL, BY COUNTRY, 2023–2030 (USD MILLION) 120 TABLE 73 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR COLPOCLEISIS, BY REGION, 2023–2030 (USD MILLION) 121 TABLE 74 NORTH AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR COLPOCLEISIS, BY COUNTRY, 2023–2030 (USD MILLION) 122 TABLE 75 EUROPE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR COLPOCLEISIS, BY COUNTRY, 2023–2030 (USD MILLION) 122 TABLE 76 ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION FOR COLPOCLEISIS, BY COUNTRY, 2023–2030 (USD MILLION) 123 TABLE 77 LATIN AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR COLPOCLEISIS, BY COUNTRY, 2023–2030 (USD MILLION) 123 TABLE 78 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR COLPORRHAPY, BY REGION, 2023–2030 (USD MILLION) 124 TABLE 79 NORTH AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR COLPORRHAPY, BY COUNTRY, 2023–2030 (USD MILLION) 125 TABLE 80 EUROPE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR COLPORRHAPY, BY COUNTRY, 2023–2030 (USD MILLION) 125 TABLE 81 ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR COLPORRHAPY, BY COUNTRY, 2023–2030 (USD MILLION) 126 TABLE 82 LATIN AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR COLPORRHAPY, BY COUNTRY, 2023–2030 (USD MILLION) 126 TABLE 83 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR SACROCOLPOPEXY, BY REGION, 2023–2030 (USD MILLION) 127 TABLE 84 NORTH AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR SACROCOLPOPEXY, BY COUNTRY, 2023–2030 (USD MILLION) 128 TABLE 85 EUROPE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR SACROCOLPOPEXY, BY COUNTRY, 2023–2030 (USD MILLION) 128 TABLE 86 ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR SACROCOLPOPEXY, BY COUNTRY, 2023–2030 (USD MILLION) 129 TABLE 87 LATIN AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR SACROCOLPOPEXY, BY COUNTRY, 2022–2030 (USD MILLION) 129 TABLE 88 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR SACROHYSTEROPEXY, BY REGION, 2023–2030 (USD MILLION) 130 TABLE 89 NORTH AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR SACROHYSTEROPEXY, BY COUNTRY, 2023–2030 (USD MILLION) 131 TABLE 90 EUROPE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR SACROHYSTEROPEXY, BY COUNTRY, 2023–2030 (USD MILLION) 131 TABLE 91 ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR SACROHYSTEROPEXY, BY COUNTRY, 2023–2030 (USD MILLION) 132 TABLE 92 LATIN AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR SACROHYSTEROPEXY, BY COUNTRY, 2022–2030 (USD MILLION) 132 TABLE 93 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR UTEROSACRAL OR SACROSPINOUS LIGAMENT FIXATION, BY REGION, 2023–2030 (USD MILLION) 133 TABLE 94 NORTH AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR UTEROSACRAL OR SACROSPINOUS LIGAMENT FIXATION, BY COUNTRY, 2023–2030 (USD MILLION) 134 TABLE 95 EUROPE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR UTEROSACRAL OR SACROSPINOUS LIGAMENT FIXATION, BY COUNTRY, 2023–2030 (USD MILLION) 134 TABLE 96 ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR UTEROSACRAL OR SACROSPINOUS LIGAMENT FIXATION, BY COUNTRY, 2023–2030 (USD MILLION) 135 TABLE 97 LATIN AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR UTEROSACRAL OR SACROSPINOUS LIGAMENT FIXATION, BY COUNTRY, 2022–2030 (USD MILLION) 135 TABLE 98 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR NON-SURGICAL, BY TYPE, 2023–2030 (USD MILLION) 136 TABLE 99 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR NON-SURGICAL, BY REGION, 2023–2030 (USD MILLION) 136 TABLE 100 NORTH AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR NON-SURGICAL, BY COUNTRY, 2023–2030 (USD MILLION) 137 TABLE 101 EUROPE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR NON-SURGICAL, BY COUNTRY, 2023–2030 (USD MILLION) 137 TABLE 102 ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR NON-SURGICAL, BY COUNTRY, 2023–2030 (USD MILLION) 138 TABLE 103 LATIN AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR NON-SURGICAL, BY COUNTRY, 2023–2030 (USD MILLION) 138 TABLE 104 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR VAGINAL PESSARY MANAGEMENT, BY REGION, 2023–2030 (USD MILLION) 139 TABLE 105 NORTH AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR VAGINAL PESSARY MANAGEMENT, BY COUNTRY, 2023–2030 (USD MILLION) 140 TABLE 106 EUROPE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR VAGINAL PESSARY MANAGEMENT, BY COUNTRY, 2023–2030 (USD MILLION) 140 TABLE 107 ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION FOR VAGINAL PESSARY MANAGEMENT, BY COUNTRY, 2023–2030 (USD MILLION) 141 TABLE 108 LATIN AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR VAGINAL PESSARY MANAGEMENT, BY COUNTRY, 2023–2030 (USD MILLION) 141 TABLE 109 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR PELVIC FLOOR MUSCLE THERAPY, BY REGION, 2023–2030 (USD MILLION) 142 TABLE 110 NORTH AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR PELVIC FLOOR MUSCLE THERAPY, BY COUNTRY, 2023–2030 (USD MILLION) 143 TABLE 111 EUROPE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR PELVIC FLOOR MUSCLE THERAPY, BY COUNTRY, 2023–2030 (USD MILLION) 143 TABLE 112 ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR PELVIC FLOOR MUSCLE THERAPY, BY COUNTRY, 2023–2030 (USD MILLION) 144 TABLE 113 LATIN AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR PELVIC FLOOR MUSCLE THERAPY, BY COUNTRY, 2023–2030 (USD MILLION) 144 TABLE 114 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 146 TABLE 115 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR CYSTOCELE, BY REGION, 2023–2030 (USD MILLION) 147 TABLE 116 NORTH AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR CYSTOCELE, BY COUNTRY, 2023–2030 (USD MILLION) 147 TABLE 117 EUROPE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR CYSTOCELE, BY COUNTRY, 2023–2030 (USD MILLION) 148 TABLE 118 ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR CYSTOCELE, BY COUNTRY, 2023–2030 (USD MILLION) 148 TABLE 119 LATIN AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR CYSTOCELE, BY COUNTRY, 2023–2030 (USD MILLION) 149 TABLE 120 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR URETHROCELE, BY REGION, 2023–2030 (USD MILLION) 150 TABLE 121 NORTH AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR URETHROCELE, BY COUNTRY, 2023–2030 (USD MILLION) 150 TABLE 122 EUROPE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR URETHROCELE, BY COUNTRY, 2023–2030 (USD MILLION) 151 TABLE 123 ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION FOR URETHROCELE, BY COUNTRY, 2023–2030 (USD MILLION) 151 TABLE 124 LATIN AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR URETHROCELE, BY COUNTRY, 2023–2030 (USD MILLION) 152 TABLE 125 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR ENTEROCELE, BY REGION, 2023–2030 (USD MILLION) 153 TABLE 126 NORTH AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR ENTEROCELE, BY COUNTRY, 2023–2030 (USD MILLION) 153 TABLE 127 EUROPE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR ENTEROCELE, BY COUNTRY, 2023–2030 (USD MILLION) 154 TABLE 128 ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR ENTEROCELE, BY COUNTRY, 2023–2030 (USD MILLION) 154 TABLE 129 LATIN AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR ENTEROCELE, BY COUNTRY, 2023–2030 (USD MILLION) 155 TABLE 130 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR UTERINE PROLAPSE, BY REGION, 2023–2030 (USD MILLION) 156 TABLE 131 NORTH AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR UTERINE PROLAPSE, BY COUNTRY, 2023–2030 (USD MILLION) 156 TABLE 132 EUROPE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR UTERINE PROLAPSE, BY COUNTRY, 2023–2030 (USD MILLION) 157 TABLE 133 ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR UTERINE PROLAPSE, BY COUNTRY, 2023–2030 (USD MILLION) 157 TABLE 134 LATIN AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR UTERINE PROLAPSE, BY COUNTRY, 2022–2030 (USD MILLION) 158 TABLE 135 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR RECTOCELE, BY REGION, 2023–2030 (USD MILLION) 159 TABLE 136 NORTH AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR RECTOCELE, BY COUNTRY, 2023–2030 (USD MILLION) 159 TABLE 137 EUROPE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR RECTOCELE, BY COUNTRY, 2023–2030 (USD MILLION) 160 TABLE 138 ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR RECTOCELE, BY COUNTRY, 2023–2030 (USD MILLION) 160 TABLE 139 LATIN AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR RECTOCELE, BY COUNTRY, 2023–2030 (USD MILLION) 161 TABLE 140 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY END USER, 2023–2030 (USD MILLION) 163 TABLE 141 HOSPITALS PER CAPITA, BY COUNTRY, 2024 164 TABLE 142 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR HOSPITALS, BY REGION, 2023–2030 (USD MILLION) 165 TABLE 143 NORTH AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION) 165 TABLE 144 EUROPE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION) 166 TABLE 145 ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION) 166 TABLE 146 LATIN AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION) 167 TABLE 147 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR SPECIALTY CLINICS, BY REGION, 2023–2030 (USD MILLION) 168 TABLE 148 NORTH AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR SPECIALTY CLINICS, BY COUNTRY, 2023–2030 (USD MILLION) 168 TABLE 149 EUROPE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR SPECIALTY CLINICS, BY COUNTRY, 2023–2030 (USD MILLION) 169 TABLE 150 ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION FOR SPECIALTY CLINICS, BY COUNTRY, 2023–2030 (USD MILLION) 169 TABLE 151 LATIN AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR SPECIALTY CLINICS, BY COUNTRY, 2023–2030 (USD MILLION) 170 TABLE 152 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR AMBULATORY SURGERY CENTERS, BY REGION, 2023–2030 (USD MILLION) 171 TABLE 153 NORTH AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR AMBULATORY SURGERY CENTERS, BY COUNTRY, 2023–2030 (USD MILLION) 171 TABLE 154 EUROPE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR AMBULATORY SURGERY CENTERS, BY COUNTRY, 2023–2030 (USD MILLION) 172 TABLE 155 ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR AMBULATORY SURGERY CENTERS, BY COUNTRY, 2023–2030 (USD MILLION) 172 TABLE 156 LATIN AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR AMBULATORY SURGERY CENTERS, BY COUNTRY, 2023–2030 (USD MILLION) 173 TABLE 157 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION) 174 TABLE 158 NORTH AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 174 TABLE 159 EUROPE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 175 TABLE 160 ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 175 TABLE 161 LATIN AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2030 (USD MILLION) 176 TABLE 162 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY REGION, 2023–2030 (USD MILLION) 178 TABLE 163 NORTH AMERICA: MACROECONOMIC INDICATORS 179 TABLE 164 NORTH AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 181 TABLE 165 NORTH AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 181 TABLE 166 NORTH AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TREATMENT, 2023–2030 (USD MILLION) 182 TABLE 167 NORTH AMERICA: SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 182 TABLE 168 NORTH AMERICA: NON-SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 183 TABLE 169 NORTH AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 183 TABLE 170 NORTH AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY END USER, 2023–2030 (USD MILLION) 184 TABLE 171 US: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 185 TABLE 172 US: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TREATMENT, 2023–2030 (USD MILLION) 185 TABLE 173 US: SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 186 TABLE 174 US: NON-SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 186 TABLE 175 US: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 187 TABLE 176 US: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY END USER, 2023–2030 (USD MILLION) 187 TABLE 177 CANADA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 188 TABLE 178 CANADA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TREATMENT, 2023–2030 (USD MILLION) 189 TABLE 179 CANADA: SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 189 TABLE 180 CANADA: NON-SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 190 TABLE 181 CANADA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 190 TABLE 182 CANADA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY END USER, 2023–2030 (USD MILLION) 191 TABLE 183 EUROPE: MACROECONOMIC INDICATORS 192 TABLE 184 EUROPE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 192 TABLE 185 EUROPE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 193 TABLE 186 EUROPE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TREATMENT, 2023–2030 (USD MILLION) 193 TABLE 187 EUROPE: SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 194 TABLE 188 EUROPE: NON-SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 194 TABLE 189 EUROPE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 195 TABLE 190 EUROPE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY END USER, 2023–2030 (USD MILLION) 195 TABLE 191 GERMANY: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 196 TABLE 192 GERMANY: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TREATMENT, 2023–2030 (USD MILLION) 197 TABLE 193 GERMANY: SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 197 TABLE 194 GERMANY: NON-SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 198 TABLE 195 GERMANY: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 198 TABLE 196 GERMANY: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY END USER, 2023–2030 (USD MILLION) 199 TABLE 197 FRANCE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 200 TABLE 198 FRANCE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TREATMENT, 2023–2030 (USD MILLION) 200 TABLE 199 FRANCE: SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 201 TABLE 200 FRANCE: NON-SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 201 TABLE 201 FRANCE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 202 TABLE 202 FRANCE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY END USER, 2023–2030 (USD MILLION) 202 TABLE 203 UK: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 204 TABLE 204 UK: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TREATMENT, 2023–2030 (USD MILLION) 204 TABLE 205 UK: SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 205 TABLE 206 UK: NON-SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 205 TABLE 207 UK: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 206 TABLE 208 UK: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY END USER, 2023–2030 (USD MILLION) 206 TABLE 209 ITALY: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 208 TABLE 210 ITALY: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TREATMENT, 2023–2030 (USD MILLION) 208 TABLE 211 ITALY: SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 209 TABLE 212 ITALY: NON-SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 209 TABLE 213 ITALY: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 210 TABLE 214 ITALY: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY END USER, 2023–2030 (USD MILLION) 210 TABLE 215 SPAIN: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 211 TABLE 216 SPAIN: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TREATMENT, 2023–2030 (USD MILLION) 212 TABLE 217 SPAIN: SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 212 TABLE 218 SPAIN: NON-SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 213 TABLE 219 SPAIN: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 213 TABLE 220 SPAIN: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY END USER, 2023–2030 (USD MILLION) 214 TABLE 221 REST OF EUROPE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 215 TABLE 222 REST OF EUROPE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TREATMENT, 2023–2030 (USD MILLION) 215 TABLE 223 REST OF EUROPE: SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 216 TABLE 224 REST OF EUROPE: NON-SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 216 TABLE 225 REST OF EUROPE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 217 TABLE 226 REST OF EUROPE: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY END USER, 2023–2030 (USD MILLION) 217 TABLE 227 ASIA PACIFIC: KEY MACROECONOMIC INDICATORS 219 TABLE 228 ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 220 TABLE 229 ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 220 TABLE 230 ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TREATMENT, 2023–2030 (USD MILLION) 221 TABLE 231 ASIA PACIFIC: SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 221 TABLE 232 ASIA PACIFIC: NON-SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 222 TABLE 233 ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 222 TABLE 234 ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY END USER, 2023–2030 (USD MILLION) 223 TABLE 235 CHINA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 224 TABLE 236 CHINA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TREATMENT, 2023–2030 (USD MILLION) 224 TABLE 237 CHINA: SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 225 TABLE 238 CHINA: NON-SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 225 TABLE 239 CHINA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 226 TABLE 240 CHINA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY END USER, 2023–2030 (USD MILLION) 226 TABLE 241 JAPAN: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 228 TABLE 242 JAPAN: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TREATMENT, 2023–2030 (USD MILLION) 228 TABLE 243 JAPAN: SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 229 TABLE 244 JAPAN: NON-SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 229 TABLE 245 JAPAN: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 230 TABLE 246 JAPAN: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY END USER, 2023–2030 (USD MILLION) 230 TABLE 247 INDIA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 232 TABLE 248 INDIA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TREATMENT, 2023–2030 (USD MILLION) 232 TABLE 249 INDIA: SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 233 TABLE 250 INDIA: NON-SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 233 TABLE 251 INDIA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 234 TABLE 252 INDIA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY END USER, 2023–2030 (USD MILLION) 234 TABLE 253 AUSTRALIA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 236 TABLE 254 AUSTRALIA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TREATMENT, 2023–2030 (USD MILLION) 236 TABLE 255 AUSTRALIA: SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 237 TABLE 256 AUSTRALIA: NON-SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 237 TABLE 257 AUSTRALIA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 238 TABLE 258 AUSTRALIA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY END USER, 2023–2030 (USD MILLION) 238 TABLE 259 SOUTH KOREA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 239 TABLE 260 SOUTH KOREA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TREATMENT, 2023–2030 (USD MILLION) 240 TABLE 261 SOUTH KOREA: SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 240 TABLE 262 SOUTH KOREA: NON-SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 241 TABLE 263 SOUTH KOREA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 241 TABLE 264 SOUTH KOREA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY END USER, 2023–2030 (USD MILLION) 242 TABLE 265 REST OF ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 243 TABLE 266 REST OF ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TREATMENT, 2023–2030 (USD MILLION) 243 TABLE 267 REST OF ASIA PACIFIC: SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 244 TABLE 268 REST OF ASIA PACIFIC: NON-SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 244 TABLE 269 REST OF ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 245 TABLE 270 REST OF ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY END USER, 2023–2030 (USD MILLION) 245 TABLE 271 LATIN AMERICA: KEY MACROECONOMIC INDICATORS 246 TABLE 272 LATIN AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 247 TABLE 273 LATIN AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 247 TABLE 274 LATIN AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TREATMENT, 2023–2030 (USD MILLION) 248 TABLE 275 LATIN AMERICA: SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 248 TABLE 276 LATIN AMERICA: NON-SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 249 TABLE 277 LATIN AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 249 TABLE 278 LATIN AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY END USER, 2023–2030 (USD MILLION) 250 TABLE 279 BRAZIL: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 251 TABLE 280 BRAZIL: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TREATMENT, 2023–2030 (USD MILLION) 251 TABLE 281 BRAZIL: SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 252 TABLE 282 BRAZIL: NON-SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 252 TABLE 283 BRAZIL: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 253 TABLE 284 BRAZIL: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY END USER, 2023–2030 (USD MILLION) 253 TABLE 285 MEXICO: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 254 TABLE 286 MEXICO: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TREATMENT, 2023–2030 (USD MILLION) 255 TABLE 287 MEXICO: SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 255 TABLE 288 MEXICO: NON-SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 256 TABLE 289 MEXICO: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 256 TABLE 290 MEXICO: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY END USER, 2023–2030 (USD MILLION) 257 TABLE 291 REST OF LATIN AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 258 TABLE 292 REST OF LATIN AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TREATMENT, 2023–2030 (USD MILLION) 258 TABLE 293 REST OF LATIN AMERICA: SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 259 TABLE 294 REST OF LATIN AMERICA: NON-SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 259 TABLE 295 REST OF LATIN AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 260 TABLE 296 REST OF LATIN AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY END USER, 2023–2030 (USD MILLION) 260 TABLE 297 MIDDLE EAST & AFRICA: KEY MACROECONOMIC INDICATORS 261 TABLE 298 MIDDLE EAST & AFRICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 262 TABLE 299 MIDDLE EAST & AFRICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TREATMENT, 2023–2030 (USD MILLION) 262 TABLE 300 MIDDLE EAST & AFRICA: SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 263 TABLE 301 MIDDLE EAST & AFRICA: NON-SURGICAL PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TYPE, 2023–2030 (USD MILLION) 263 TABLE 302 MIDDLE EAST & AFRICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 264 TABLE 303 MIDDLE EAST & AFRICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY END USER, 2023–2030 (USD MILLION) 264 TABLE 304 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2022–2025 266 TABLE 305 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET: DEGREE OF COMPETITION 268 TABLE 306 REGION FOOTPRINT 272 TABLE 307 PRODUCT FOOTPRINT 273 TABLE 308 TREATMENT FOOTPRINT 274 TABLE 309 APPLICATION FOOTPRINT 274 TABLE 310 LIST OF START-UPS/SMES 277 TABLE 311 COMPETITIVE BENCHMARKING OF START-UPS/SMES 278 TABLE 312 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET: PRODUCT LAUNCHES/APPROVALS, 2022–2025 281 TABLE 313 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET: DEALS, 2022–2025 282 TABLE 314 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET: OTHER DEVELOPMENTS, 2022–2025 283 TABLE 315 BOSTON SCIENTIFIC CORPORATION: COMPANY OVERVIEW 284 TABLE 316 BOSTON SCIENTIFIC CORPORATION: PRODUCTS OFFERED 285 TABLE 317 BOSTON SCIENTIFIC CORPORATION: DEALS 286 TABLE 318 COLOPLAST GROUP: COMPANY OVERVIEW 287 TABLE 319 COLOPLAST GROUP: PRODUCTS OFFERED 289 TABLE 320 INTUITIVE SURGICAL OPERATIONS, INC.: COMPANY OVERVIEW 290 TABLE 321 INTUITIVE SURGICAL OPERATIONS, INC.: PRODUCTS OFFERED 291 TABLE 322 INTUITIVE SURGICAL OPERATIONS, INC.: PRODUCT LAUNCHES/APPROVALS 292 TABLE 323 COOPERCOMPANIES: COMPANY OVERVIEW 293 TABLE 324 COOPERCOMPANIES: PRODUCTS OFFERED 294 TABLE 325 COOPERCOMPANIES: DEALS 295 TABLE 326 JOHNSON & JOHNSON: COMPANY OVERVIEW 296 TABLE 327 JOHNSON & JOHNSON: PRODUCTS OFFERED 297 TABLE 328 JOHNSON & JOHNSON: PRODUCT LAUNCHES/APPROVALS 298 TABLE 329 JOHNSON & JOHNSON: DEALS 298 TABLE 330 JOHNSON & JOHNSON: OTHER DEVELOPMENTS 298 TABLE 331 GE HEALTHCARE: COMPANY OVERVIEW 300 TABLE 332 GE HEALTHCARE: PRODUCTS OFFERED 301 TABLE 333 GE HEALTHCARE: PRODUCT LAUNCHES/APPROVALS 302 TABLE 334 GE HEALTHCARE: DEALS 302 TABLE 335 GE HEALTHCARE: OTHER DEVELOPMENTS 302 TABLE 336 INTEGRA LIFESCIENCES CORPORATION: COMPANY OVERVIEW 303 TABLE 337 INTEGRA LIFESCIENCES CORPORATION: PRODUCTS OFFERED 304 TABLE 338 B. BRAUN SE: COMPANY OVERVIEW 305 TABLE 339 B. BRAUN SE: PRODUCTS OFFERED 306 TABLE 340 B. BRAUN SE: DEALS 307 TABLE 341 PFM MEDICAL GMBH: COMPANY OVERVIEW 308 TABLE 342 PFM MEDICAL GMBH: PRODUCTS OFFERED 308 TABLE 343 CALDERA MEDICAL: COMPANY OVERVIEW 309 TABLE 344 CALDERA MEDICAL: PRODUCTS OFFERED 309 TABLE 345 CALDERA MEDICAL: DEALS 310 FIGURE 1 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET SEGMENTATION 31 FIGURE 2 RESEARCH DESIGN 34 FIGURE 3 TOP-DOWN APPROACH 41 FIGURE 4 DATA TRIANGULATION 42 FIGURE 5 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY PRODUCT, 2025 VS. 2030 (USD MILLION) 45 FIGURE 6 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY TREATMENT, 2025 VS. 2030 (USD MILLION) 46 FIGURE 7 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION) 47 FIGURE 8 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 48 FIGURE 9 GEOGRAPHICAL SNAPSHOT OF PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET 49 FIGURE 10 RISE IN FEMALE GERIATRIC POPULATION TO DRIVE MARKET 51 FIGURE 11 HOSPITALS AND CHINA ACCOUNTED FOR SIGNIFICANT SHARES IN 2024 52 FIGURE 12 ASIA PACIFIC TO EXHIBIT FASTEST GROWTH DURING FORECAST PERIOD 53 FIGURE 13 INDIA TO BE FASTEST-GROWING MARKET DURING FORECAST PERIOD 54 FIGURE 14 PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET DYNAMICS 55 FIGURE 15 TRENDS AND DISRUPTIONS IMPACTING CUSTOMER BUSINESS 61 FIGURE 16 VALUE CHAIN ANALYSIS 64 FIGURE 17 SUPPLY CHAIN ANALYSIS 65 FIGURE 18 ECOSYSTEM ANALYSIS 66 FIGURE 19 INVESTMENT AND FUNDING SCENARIO, 2020–2025 (USD MILLION) 67 FIGURE 20 PATENT ANALYSIS 70 FIGURE 21 PORTER’S FIVE FORCES ANALYSIS 80 FIGURE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP FOUR PRODUCTS 82 FIGURE 23 KEY BUYING CRITERIA FOR TOP FOUR PRODUCTS 83 FIGURE 24 IMPACT OF AI ON PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET 85 FIGURE 25 NORTH AMERICA: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET SNAPSHOT 180 FIGURE 26 ASIA PACIFIC: PELVIC ORGAN PROLAPSE/PELVIC FLOOR RECONSTRUCTION MARKET SNAPSHOT 219 FIGURE 27 REVENUE ANALYSIS OF KEY PLAYERS, 2022–2024 (USD MILLION) 267 FIGURE 28 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2024 268 FIGURE 29 COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 271 FIGURE 30 COMPANY FOOTPRINT 272 FIGURE 31 COMPANY EVALUATION MATRIX (START-UPS/SMES), 2024 276 FIGURE 32 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND FIVE-YEAR STOCK BETA OF KEY VENDORS 279 FIGURE 33 EV/EBITDA OF KEY VENDORS 280 FIGURE 34 BRAND/PRODUCT COMPARATIVE ANALYSIS 280 FIGURE 35 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT 285 FIGURE 36 COLOPLAST GROUP: COMPANY SNAPSHOT 288 FIGURE 37 INTUITIVE SURGICAL OPERATIONS, INC.: COMPANY SNAPSHOT 291 FIGURE 38 COOPERCOMPANIES: COMPANY SNAPSHOT 294 FIGURE 39 JOHNSON & JOHNSON: COMPANY SNAPSHOT 297 FIGURE 40 GE HEALTHCARE: COMPANY SNAPSHOT 301 FIGURE 41 INTEGRA LIFESCIENCES CORPORATION: COMPANY SNAPSHOT 304 FIGURE 42 B. BRAUN SE: COMPANY SNAPSHOT 306

同分類最新報告(醫療器材)

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理,提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們